An analysis comparing phase III ASCENT-03 and TROPION-Breast02 trials reported that TROP2-directed antibody–drug conjugates improved progression-free survival versus standard chemotherapy in patients with immunotherapy-ineligible metastatic triple-negative breast cancer. The comparison focused on consistency across study populations rather than a single head-to-head design. The reported pattern supports continued clinical relevance of TROP2 ADC strategies as frontline options in a defined TNBC setting, where treatment selection often hinges on prior therapy eligibility for immunotherapy.
Get the Daily Brief